Skip to main content

Advertisement

SpringerLink
Log in

Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Drug metabolizing enzymes participate in the neutralizing of xenobiotics and biotransformation of drugs. Human cytochrome P450, particularly CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5, play an important role in drug metabolism. The genes encoding the CYP enzymes are polymorphic, and extensive data have shown that certain alleles confer reduced enzymatic function. The goal of this study was to determine the frequencies of important allelic variants of CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5 in the Jordanian population and compare them with the frequency in other ethnic groups. Genotyping of CYP1A1(m1 and m2), CYP2C9 (*2 and *3), CYP2C19 (*2 and *3), CYP3A4*5, CYP3A5 (*3 and *6), was carried out on Jordanian subjects. Different variants allele were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP). CYP1A1 allele frequencies in 290 subjects were 0.764 for CYP1A1*1, 0.165 for CYP1A1*2A and 0.071 for CYP1A1*2C. CYP2C9 allele frequencies in 263 subjects were 0.797 for CYP2C9*1, 0.135 for CYP2C9*2 and 0.068 for CYP2C9*3. For CYP2C19, the frequencies of the wild type (CYP2C19*1) and the nonfunctional (*2 and *3) alleles were 0.877, 0.123 and 0, respectively. Five subjects (3.16 %) were homozygous for *2/*2. Regarding CYP3A4*1B, only 12 subjects out of 173 subjects (6.9 %) were heterozygote with none were mutant for this polymorphism. With respect to CYP3A5, 229 were analyzed, frequencies of CYP3A5*1,*3 and *6 were 0.071, 0.925 and 0.0022, respectively. Comparing our data with that obtained in several Caucasian, African-American and Asian populations, Jordanians are most similar to Caucasians with regard to allelic frequencies of the tested variants of CYP1A1, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weizmann Institute of Science (2011) GeneCard for protein-coding CYP1A1. http://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP1A1. Accessed 5 March 2011

  2. McManus ME, Burgess WM, Veronese ME, Huggett A, Quattrochi LC, Tukey RH (1990) Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res 50:3367–3376

    PubMed  CAS  Google Scholar 

  3. Munoz S, Vollrath V, Vallejos MP, Miquel JF, Covarrubias C, Raddatz A, Chianale J (1998) Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8:343–351

    Article  PubMed  CAS  Google Scholar 

  4. Garte S (1998) The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 19:1329–1332

    Article  PubMed  CAS  Google Scholar 

  5. Quinones L, Berthou F, Varela N, Simon B, Gil L, Lucas D (1999) Ethnic susceptibility to lung cancer: differences in CYP2E1, CYP1A1 and GSTM1 genetic polymorphisms between French Caucasian and Chilean populations. Cancer Lett 141:167–171

    Article  PubMed  CAS  Google Scholar 

  6. Shaffi SM, Shah MA, Bhat IA, Koul P, Ahmad SN, Siddiqi MA (2009) CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev 10:651–656

    PubMed  Google Scholar 

  7. San Jose C, Cabanillas A, Benitez J, Carrillo JA, Jimenez M, Gervasini G (2010) CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study. BMC Cancer 10:463

    Article  PubMed  Google Scholar 

  8. Cosma G, Crofts F, Currie D, Wirgin I, Toniolo P, Garte SJ (1993) Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol Biomarkers Prev 2:53–57

    PubMed  CAS  Google Scholar 

  9. Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S (2009) Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study. Indian J Med Sci 63:13–20

    Article  PubMed  CAS  Google Scholar 

  10. Boyapati SM, Shu XO, Gao YT, Cai Q, Jin F, Zheng W (2005) Polymorphisms in CYP1A1 and breast carcinoma risk in a population-based case-control study of Chinese women. Cancer 103:2228–2235

    Article  PubMed  CAS  Google Scholar 

  11. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242–251

    PubMed  CAS  Google Scholar 

  12. Entrez (2011) Gene summary CYP2C19. http://www.ncbi.nlm0.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=full_report&list_uids=1557. Accessed June 2011

  13. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1:167–170

    Article  PubMed  CAS  Google Scholar 

  14. Ali ZK, Kim RJ, Ysla FM (2009) CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Devel 12:108–114

    PubMed  CAS  Google Scholar 

  15. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12:251–263

    Article  PubMed  CAS  Google Scholar 

  16. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538

    Article  PubMed  CAS  Google Scholar 

  17. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439

    Article  PubMed  CAS  Google Scholar 

  18. Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R (2007) Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med 4:157–169

    Article  PubMed  CAS  Google Scholar 

  19. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436

    Article  PubMed  CAS  Google Scholar 

  20. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341–349

    Article  PubMed  CAS  Google Scholar 

  21. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR (1996) Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 6:527–533

    Article  PubMed  CAS  Google Scholar 

  22. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628–631

    Article  PubMed  CAS  Google Scholar 

  23. Nasu K, Kubota T, Ishizaki T (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7:405–409

    Article  PubMed  CAS  Google Scholar 

  24. Wang SL, Huang J, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37–42

    Article  PubMed  CAS  Google Scholar 

  25. Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302

    PubMed  CAS  Google Scholar 

  26. Fukasawa T, Suzuki A, Otani K (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 32:333–341

    Article  PubMed  CAS  Google Scholar 

  27. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422

    PubMed  Google Scholar 

  28. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598

    PubMed  Google Scholar 

  29. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111–121

    Article  PubMed  CAS  Google Scholar 

  30. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–1294

    Article  PubMed  CAS  Google Scholar 

  31. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165–206

    Article  PubMed  CAS  Google Scholar 

  32. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–388

    Article  PubMed  CAS  Google Scholar 

  33. Lakhman SS, Ma Q, Morse GD (2009) Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 10:1323–1339

    Article  PubMed  CAS  Google Scholar 

  34. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207–213

    PubMed  CAS  Google Scholar 

  35. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–779

    Article  PubMed  CAS  Google Scholar 

  36. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391

    Article  PubMed  CAS  Google Scholar 

  37. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233–1235

    Article  PubMed  CAS  Google Scholar 

  38. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477–483

    Article  PubMed  CAS  Google Scholar 

  39. Lowi MR (1995) Water and power: the politics of a scarce resource in the Jordan River basin. Cambridge University Press, Cambridge

    Google Scholar 

  40. Central Intelligence Agency (2012) The World Factbook. https://www.cia.gov/library/publications/the-world-factbook/fields/2075.html. Accessed 18 Feb 2012

  41. The Royal Hashemite Court Keys to the Kingdom—The People of Jordan. http://www.kinghussein.gov.jo/people.html. Accessed 18 Feb 2012

  42. Brooker R (ed) (2005) Genetics, analysis and principles, 2nd edn. McGraw-Hill, New York

    Google Scholar 

  43. Graph Pad Software Inc http://www.graphpad.com/quickcalcs/chisquared1.cfm. Accessed 20 February 2011

  44. Sanford B (1990) Pharmaceutical statistics: practical and clinical application. Marcel Dekker, Inc., New York

    Google Scholar 

  45. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell’Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239–1248

    PubMed  CAS  Google Scholar 

  46. Cascorbi I, Brockmoller J, Roots I (1996) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56:4965–4969

    PubMed  CAS  Google Scholar 

  47. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263:131–133

    Article  PubMed  CAS  Google Scholar 

  48. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I (1997) CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. Pharmacogenetics 7:303–307

    Article  PubMed  CAS  Google Scholar 

  49. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K (1991) Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177–5180

    PubMed  CAS  Google Scholar 

  50. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I (1994) Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investig 72:240–248

    Article  PubMed  CAS  Google Scholar 

  51. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596–603

    Article  PubMed  CAS  Google Scholar 

  52. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243–247

    Article  PubMed  CAS  Google Scholar 

  53. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277–280

    Article  PubMed  CAS  Google Scholar 

  54. Marin-Leblanc M, Perreault S, Bahroun I, Lapointe M, Mongrain I, Provost S, Turgeon J, Talajic M, Brugada R, Phillips M, Tardif JC, Dube MP (2012) Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics 13:21–29

    Article  PubMed  CAS  Google Scholar 

  55. Tan GM, Wu E, Lam YY, Yan BP (2010) Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11:439–448

    Article  PubMed  CAS  Google Scholar 

  56. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59–64

    Article  PubMed  CAS  Google Scholar 

  57. Perry E (2011) Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms. Am J Health Syst Pharm 68:529–532

    Article  PubMed  CAS  Google Scholar 

  58. Shi WX, Chen SQ (2004) Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 10:1961–1963

    PubMed  CAS  Google Scholar 

  59. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:3–28

    PubMed  CAS  Google Scholar 

  60. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338:299–305

    Article  PubMed  CAS  Google Scholar 

  61. Dawood A (2007) Polymorphisms of cytochrome P450 xenobiotic-metabolizing enzymes cyp2D6 and cyp3A4*1B and susceptability to atherosclerosis. In: Analytical toxicology science. University of Jordan, Amman, p 74

  62. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 12:289

    PubMed  CAS  Google Scholar 

  63. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110:553–560

    Article  PubMed  Google Scholar 

  64. Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M, Gonzalez M, Brunet S, Batlle M, Cervera J, Sanz MA (2007) Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 136:590–596

    Article  PubMed  CAS  Google Scholar 

  65. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12:355–366

    Article  PubMed  CAS  Google Scholar 

  66. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A (2003) The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13:607–618

    Article  PubMed  CAS  Google Scholar 

  67. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668–1671

    PubMed  Google Scholar 

  68. Hardy GH (1908) Mendelian proportions in a mixed population. Science 28:49–50

    Article  PubMed  CAS  Google Scholar 

  69. Rodriguez S, Gaunt TR, Day IN (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505–514

    Article  PubMed  Google Scholar 

  70. Gonzalez AM, Karadsheh N, Maca-Meyer N, Flores C, Cabrera VM, Larruga JM (2008) Mitochondrial DNA variation in Jordanians and their genetic relationship to other Middle East populations. Ann Hum Biol 35:212–231

    Article  PubMed  Google Scholar 

  71. London SJ, Smart J, Daly AK (2000) Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 28:147–155

    Article  PubMed  CAS  Google Scholar 

  72. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275–280

    Article  PubMed  CAS  Google Scholar 

  73. Weber WW (1999) Populations and genetic polymorphisms. Mol Diagn 4:299–307

    Article  PubMed  CAS  Google Scholar 

  74. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I (1998) High frequency of CYP1A1 mutations in a Turkish population. Arch Toxicol 72:215–218

    Article  PubMed  CAS  Google Scholar 

  75. Song N, Tan W, Xing D, Lin D (2001) CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22:11–16

    Article  PubMed  CAS  Google Scholar 

  76. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S (1998) Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis 19:813–817

    Article  PubMed  CAS  Google Scholar 

  77. Burian M, Grosch S, Tegeder I, Geisslinger G (2002) Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 54:518–521

    Article  PubMed  CAS  Google Scholar 

  78. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447–450

    Article  PubMed  CAS  Google Scholar 

  79. Zand N, Tajik N, Moghaddam AS, Milanian I (2007) Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 34:102–105

    Article  PubMed  CAS  Google Scholar 

  80. Kudzi W, Dodoo AN, Mills JJ (2009) Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10:124

    Article  PubMed  Google Scholar 

  81. Celebi A, Kocaman O, Savli H, Aygun C, Konduk BT, Senturk O, Hulagu S (2009) The prevalence of CYP2C19 mutations in Turkish patients with dyspepsia. Turk J Gastroenterol 20:161–164

    PubMed  Google Scholar 

  82. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419–426

    Article  PubMed  CAS  Google Scholar 

  83. Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N (2011) Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 38:5449–5452

    Article  PubMed  CAS  Google Scholar 

  84. Sameer AE, Amany GM, Abdela AA, Fadel SA (2009) CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol 16:e156–e162

    PubMed  Google Scholar 

  85. Garsa AA, McLeod HL, Marsh S (2005) CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet 6:19

    Article  PubMed  Google Scholar 

  86. Sayütoúlu MA, Yildiz I, Hatirnaz O, Ozbek U (2006) Common Cytochrome p4503A (CYP3A4 and CYP3A5) and Thiopurine S-Methyl Transferase (TPMT) Polymorphisms In Turkish Population. Turkish Journal of Medical Sciences. 36:11–15

    Google Scholar 

  87. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J (2005) Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit 27:819–821

    Article  PubMed  CAS  Google Scholar 

  88. Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Bjorkman A, Ashton M, Gil JP (2009) Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 65:355–363

    Article  PubMed  CAS  Google Scholar 

  89. Kudzi W, Dodoo AN, Mills JJ (2010) Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 11:111

    Article  PubMed  Google Scholar 

  90. Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, Imbenotte M, Broly F, Lacarelle B, Lhermitte M (2006) Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica 36:1191–1200

    Article  PubMed  CAS  Google Scholar 

  91. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, Mizugaki M (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417–421

    Article  PubMed  CAS  Google Scholar 

  92. Park SY, Kang YS, Jeong MS, Yoon HK, Han KO (2008) Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther 33:61–65

    Article  PubMed  CAS  Google Scholar 

  93. Balram C, Zhou Q, Cheung YB, Lee EJ (2003) CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59:123–126

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank all who participated in the study. This study was supported in part by unconditional grant from the Deanship of Scientific Research (Jordan University, Jordan). The study sponsors had no part in the study design, data collection, data analysis, data interpretations or in the writing of the manuscript. The sponsors had no role in the decision to submit the paper for publication.

Conflict of interest

None of the authors has any financial or personal relationships that could potentially be perceived as influencing our research.

Author information

Authors and Affiliations

  1. Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, 11942, Jordan

    Al-Motassem Yousef, Nailya R. Bulatova, Nancy Hakooz, Hisham Qusa, Farah Zahran, Farah Hasan, Imad Zaloom, Ghada Khayat, Rawan Al-Zmili & Ola Al-Diab

  2. School of Medicine, University of Manchester, Manchester, UK

    William Newman

  3. Molecular Biology Research Laboratory, Department of Biochemistry, Faculty of Medicine, University of Jordan, Amman, Jordan

    Said Ismail, Nidaa Anwar Ababneh & Randa Naffa

Authors
  1. Al-Motassem Yousef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nailya R. Bulatova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nancy Hakooz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Said Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisham Qusa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Farah Zahran
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nidaa Anwar Ababneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Farah Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Imad Zaloom
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ghada Khayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rawan Al-Zmili
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Randa Naffa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ola Al-Diab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Al-Motassem Yousef.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yousef, AM., Bulatova, N.R., Newman, W. et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 39, 9423–9433 (2012). https://doi.org/10.1007/s11033-012-1807-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1807-5

Keywords

Search

Navigation